Your browser doesn't support javascript.
loading
IL-16 expression is increased in the skin and sera of patients with systemic sclerosis.
Kawabata, Kazuo; Makino, Takamitsu; Makino, Katsunari; Kajihara, Ikko; Fukushima, Satoshi; Ihn, Hironobu.
Affiliation
  • Kawabata K; Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto city, Japan.
  • Makino T; Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto city, Japan.
  • Makino K; Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto city, Japan.
  • Kajihara I; Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto city, Japan.
  • Fukushima S; Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto city, Japan.
  • Ihn H; Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto city, Japan.
Rheumatology (Oxford) ; 59(3): 519-523, 2020 03 01.
Article in En | MEDLINE | ID: mdl-31377804
OBJECTIVES: SSc is an autoimmune disease with chronic and persistent inflammation in its pathogenesis. To examine the expression pattern of IL-16 in SSc lesions, the serum concentration of IL-16 in SSc patients and the relationship between serum IL-16 levels and the clinical symptoms of SSc were investigated. METHODS: Using immunohistochemical analysis, we examined the quantity and localization of IL-16 in affected skin obtained from SSc patients. We also measured serum levels of IL-16 in SSc patients using an ELISA. We then validated the correlation between serum IL-16 levels and clinical symptoms in patients with SSc. RESULTS: In the skin, IL-16 was expressed on the lymphocytes around the capillaries. Furthermore, the proportion of IL-16-positive cells was statistically higher in patients with dcSSc than in those with lcSSc patients (43.9 vs 29.1%, P < 0.05). The serum IL-16 levels in SSc patients were statistically significant elevated compared with healthy controls (297.0 vs 194.9 pg/ml, P < 0.05). Increased serum IL-16 levels in SSc patients were correlated with the proportion classified as dcSSc, skin score and the presence of cutaneous symptoms of erythema and pigmentation. CONCLUSION: The regional up-regulation of IL-16 in the skin is not only associated with skin sclerosis, but also with systemic IL-16 activation. IL-16 may play a role in the pathogenesis of SSc. Moreover, serum IL-16 levels may be useful as a biomarker for determining the severity of the skin sclerosis. Inhibiting IL-16 activation may be effective in treating SSc.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Skin / Interleukin-16 Type of study: Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2020 Document type: Article Affiliation country: Japan Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Skin / Interleukin-16 Type of study: Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2020 Document type: Article Affiliation country: Japan Country of publication: United kingdom